hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06267950, orgStudyIdInfo id: PILUO-INFANT, briefTitle: Effect of Oral Feeding in Infants With Pierre Robin Syndrome, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-29, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Zeng Changhao, class: OTHER, descriptionModule briefSummary: This was a randomized controlled study. The infants enrolled were randomly divided into the IOE group (with Intermittent Oro-Esophageal Tube Feeding) and the PNG group (with Nasogastric Tube Feeding), all receiving systemic therapy. Before and after 4-week treatment, pulmonary infection, swallowing function, nutritional status and body weight between the two group were compared., conditionsModule conditions: Pierre Robin Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: systematic therapy, interventions name: intermittent oro-esophageal tube feeding, interventions name: gastric tube feeding, outcomesModule primaryOutcomes measure: Number of patients diagnosed as the pulmonary infection "Positive", secondaryOutcomes measure: Nutritional status-total protein, secondaryOutcomes measure: Nutritional status-hemoglobin, secondaryOutcomes measure: Nutritional status-albumin, secondaryOutcomes measure: Body weight, secondaryOutcomes measure: The Functional Oral Intake Scale for Infants, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 12 Months, stdAges: CHILD, contactsLocationsModule locations facility: Hsinchu Rehabilitation Hospital, status: RECRUITING, city: Xinzhu, country: Taiwan, contacts name: Haim Liu, Master, role: CONTACT, geoPoint lat: 22.46205, lon: 120.47335, hasResults: False
protocolSection identificationModule nctId: NCT06267937, orgStudyIdInfo id: 101, briefTitle: Hip Fractures in Chile: Implications for Public Health Policy and Healthcare Delivery, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-03-10, primaryCompletionDateStruct date: 2023-03-10, completionDateStruct date: 2024-01-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: University of Chile, class: OTHER, collaborators name: Instituto Sistemas Complejos de Ingeniería, Universidad de Chile, Santiago, Chile, descriptionModule briefSummary: Hip fractures in individuals aged 60 and above pose significant challenges in terms of morbidity, mortality, and healthcare costs. While countries like the United Kingdom and Australia have optimized their healthcare systems for timely management of hip fractures, the situation in Chile presents distinct challenges due to its mixed healthcare system. This study aims to assess survival rates following hip fractures in Chile and identify associated risk factors using national databases from 2012 to 2018. A comprehensive analysis of 35,520 patients revealed that factors such as age, type of health insurance, access to surgery, and treatment in public hospitals significantly influence mortality rates after hip fractures. The study found that patients with hip fractures experience lower 5-year survival rates compared to the general population, particularly when affiliated with public insurance and treated in public institutions. Modifiable factors like delayed surgery and prolonged hospital stays contribute to increased mortality rates. The findings underscore the urgent need for optimized public health policies and healthcare delivery systems to enhance outcomes for hip fracture patients in Chile.Hip fractures in individuals aged 60 and above pose significant challenges in terms of morbidity, mortality, and healthcare costs. While countries like the United Kingdom and Australia have optimized their healthcare systems for timely management of hip fractures, the situation in Chile presents distinct challenges due to its mixed healthcare system. This study aims to assess survival rates following hip fractures in Chile and identify associated risk factors using national databases from 2012 to 2018., conditionsModule conditions: Hip Fractures, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 46380, type: ACTUAL, armsInterventionsModule interventions name: Access to surgery, interventions name: type of intitution, outcomesModule primaryOutcomes measure: survival after hip fracture, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: hospital Clinico Universidad de Chile, city: Santiago, state: Region Metropolitana, zip: 8380456, country: Chile, geoPoint lat: -33.45694, lon: -70.64827, hasResults: False
protocolSection identificationModule nctId: NCT06267924, orgStudyIdInfo id: Olith10703, briefTitle: SENSE-VM: Safety and Effectiveness of a Novel Medical Device for Symptom Ease in Vestibular Migraines, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Otolith Labs, class: INDUSTRY, collaborators name: MCRA, descriptionModule briefSummary: The goal of this virtual clinical trial is to compare the effectiveness of two study devices in providing temporary relief to adults aged 18-75 who suffer from symptoms of chronic Vestibular Migraines (VM), also known as Migraine Associated Vertigo.Participants will be:* Enrolled up to 50 days; enrollment, 14 days in Baseline Phase (no device), 7 days in Transition Phase, 28 days in Treatment Phase (study device)* Randomized and stratified into groups based on the referring clinic to be assigned one study device* Asked to use the study device as instructed by the study coordinator* Asked to submit daily diaries reporting their symptoms and use of device, and to participate in tele-health visits with study coordinators* Asked to provide their vertigo diagnosis from their physician* Compensated for their participationResearchers will compare the randomized groups to determine which group responds better to which device., conditionsModule conditions: Vestibular Migraine, conditions: Migraine Associated Vertigo, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The proposed clinical trial for the study device will be a randomized, sham-controlled, double-blind study with two-parallel arms (active/sham device)., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Otoband Experimental, interventions name: Otoband Sham, outcomesModule primaryOutcomes measure: DHI Change in Scores, secondaryOutcomes measure: Number of related adverse events, secondaryOutcomes measure: Change in number of vestibular migraine episodes weekly, secondaryOutcomes measure: Global Impression of Change (severity of episodes), secondaryOutcomes measure: DHI change from transition to end of study, secondaryOutcomes measure: Device responder rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Otolith Labs, city: Washington, state: District of Columbia, zip: 20001, country: United States, geoPoint lat: 38.89511, lon: -77.03637, hasResults: False
protocolSection identificationModule nctId: NCT06267898, orgStudyIdInfo id: EBMT- 842205547, briefTitle: Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML, statusModule overallStatus: COMPLETED, startDateStruct date: 2009-11-01, primaryCompletionDateStruct date: 2015-01-29, completionDateStruct date: 2015-05-21, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: European Society for Blood and Marrow Transplantation, class: NETWORK, collaborators name: Novartis, descriptionModule briefSummary: Stem cell transplantation and blood product transfusions are standard of care for Myelodysplastic Syndromes (MDS). Several studies have shown changes in serum ferritin and non-transferrin-bound iron (NTBI) in patients undergoing stem cell transplantation. A large proportion of MDS patients are at risk for organ damage from tissue siderosis, due to the development of iron overload.Toxic effects of iron may play an important role in the complications associated with HSCT. Iron chelation therapy may reduce the acute and chronic treatment-related toxicity by removing excess of iron, iron radicals and reactive oxygen species (ROS).There is little information about the efficacy and safety of iron chelation in MDS patients. This audit wants to evaluate the effect of iron toxicity on treatment-related mortality in untreated, adult MDS or CMML patients during and after treatment with myeloablative conditioning (MAC) and reduced intensity conditioning (RIC) allo-HSCT, by prospectively collecting data from 200 MDS or CMML patients from 2009 onwards., conditionsModule conditions: MDS, conditions: CMML, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 222, type: ACTUAL, outcomesModule primaryOutcomes measure: non-relapse mortality (treatment related mortality)., secondaryOutcomes measure: treatment-related toxic effects, secondaryOutcomes measure: relapse rate, secondaryOutcomes measure: event-free survival, secondaryOutcomes measure: overall survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Antwerp University Hospital (UZA), city: Antwerp, zip: 2650, country: Belgium, geoPoint lat: 51.21989, lon: 4.40346, locations facility: University Hospital Gasthuisberg, city: Leuven, zip: 3000, country: Belgium, geoPoint lat: 50.87959, lon: 4.70093, locations facility: University of Liege, city: Liege, zip: 4000, country: Belgium, geoPoint lat: 50.63373, lon: 5.56749, locations facility: Charles University Hospital, city: Pilsen, zip: 304 60, country: Czechia, geoPoint lat: 49.74747, lon: 13.37759, locations facility: University Hospital, city: Essen, zip: 45122, country: Germany, geoPoint lat: 51.45657, lon: 7.01228, locations facility: University Hospital Leipzig, city: Leipzig, zip: 04103, country: Germany, geoPoint lat: 51.33962, lon: 12.37129, hasResults: False
protocolSection identificationModule nctId: NCT06267885, orgStudyIdInfo id: Children NOF fracture fixation, briefTitle: Fixation of Fracture Neck of Femur in Children, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-02, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Find the best way for fixation of fracture neck of femur in children either by cannulated screws or wagner's technique, conditionsModule conditions: Fracture Neck of Femur, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 42, type: ESTIMATED, armsInterventionsModule interventions name: Cannulated screws vs wagner's technique, outcomesModule primaryOutcomes measure: The better method for fixation of fracture neck of femur, eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 14 Years, stdAges: CHILD, contactsLocationsModule locations facility: Assiut university, city: Assiut, country: Egypt, contacts name: Mina Maged, role: CONTACT, geoPoint lat: 27.18096, lon: 31.18368, hasResults: False
protocolSection identificationModule nctId: NCT06267859, orgStudyIdInfo id: No. 2 of 2023/11/7, briefTitle: Development of Methods for Effective Treatment and Improvement of Common Somatic Diseases in Children, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-08, primaryCompletionDateStruct date: 2033-12-30, completionDateStruct date: 2034-01-30, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Tashkent Pediatric Medical Institute, class: OTHER, descriptionModule briefSummary: The goal of the clinical study is to clarify the course of common congenital, infectious, and non-infectious diseases in children living in Uzbekistan, and to develop methods for their treatment and rehabilitation.The main questions it aims to answer:* Analysis of common congenital diseases among children;* Analysis of commonly diagnosed bronchopulmonary and cardiovascular diseases among children;* Based on the results of the primary research, common diseases among children will be identified;* Analysis of existing treatment methods and their effectiveness;* Development of modern methods of treatment and rehabilitation of children., conditionsModule conditions: Respiratory Diseases, conditions: Congenital Heart Defects, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: identification of children from the group of "frequently ill children", primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: working with children from the "frequently ill children" group, whoMasked: PARTICIPANT, enrollmentInfo count: 110, type: ESTIMATED, armsInterventionsModule interventions name: The use of a combination of microelements and vitamins against the background of physiotherapy, outcomesModule primaryOutcomes measure: Working with archival documentation., primaryOutcomes measure: Formation of a group of patients to study immunity and the antioxidant system in venous blood., primaryOutcomes measure: Clinical scientific research., primaryOutcomes measure: Clinical trial evaluation., eligibilityModule sex: ALL, minimumAge: 3 Days, maximumAge: 15 Years, stdAges: CHILD, contactsLocationsModule locations facility: Turdieva Shokhida Tolkunovna, status: RECRUITING, city: Tashkent, state: Yunus-obad District, zip: 100140, country: Uzbekistan, contacts name: Shokhida T Turdieva, M.D., D.Sc., role: CONTACT, phone: +998935872570, email: Shohidahon69@mail.ru, contacts name: Kholida B Abdurashidova, role: CONTACT, phone: +998935092934, email: otdel.nayka@mail.ru, contacts name: Gulmira R Nasirova, Ph.D., role: SUB_INVESTIGATOR, geoPoint lat: 41.26465, lon: 69.21627, hasResults: False
protocolSection identificationModule nctId: NCT06267820, orgStudyIdInfo id: 2010, briefTitle: Postoperative Pain Control by Adding Ketorolac to Bupivacaine in Transversus Abdominis Plane Block in Children, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2023-12-01, completionDateStruct date: 2023-12-10, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: Control of of pain in children is fundamental. TAP block is associated with less side effects compared with other neuraxial techniques especially when done under ultrasound guidance.Ketorolac has analgesic effect comparable to morphine. Children were arranged randomly into two equal groups, forty-five children in each.Group (K) (n= 45): received ultrasound guided TAP block with bupivacaine 0.25% (0.5 ml/kg) and ketorolac (0.5 mg/kg).Group (T) (n =45): received ultrasound guided TAP block with bupivacaine 0.25% (0.5 ml/kg), conditionsModule conditions: Postoperative Pain, Acute, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 90, type: ACTUAL, armsInterventionsModule interventions name: Bupivacain, interventions name: Ketorolac, outcomesModule primaryOutcomes measure: 1st analgesic requirement, primaryOutcomes measure: Number of patients who requested analgesia, secondaryOutcomes measure: heart rate, secondaryOutcomes measure: Total rescue analgesia, secondaryOutcomes measure: Satisfaction of the parents regarding their children analgesia, secondaryOutcomes measure: Number of children in each group who required analgesia in the first 24 h postoperatively, secondaryOutcomes measure: blood pressure, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Fouad Ibrahim Soliman, city: Sohag, zip: 52514, country: Egypt, geoPoint lat: 26.55695, lon: 31.69478, hasResults: False
protocolSection identificationModule nctId: NCT06267807, orgStudyIdInfo id: 114369, secondaryIdInfos id: NL84520.091.23, type: OTHER, domain: Protocol ID METC, briefTitle: Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders, acronym: LENS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-27, primaryCompletionDateStruct date: 2025-03-13, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Radboud University Medical Center, class: OTHER, descriptionModule briefSummary: To get a better insight into the central conducting lymphatic system in adult volunteers with Noonan Syndrome (NS) without clinical symptoms or signs of lymphatic disease compared to NS and CardioFacioCutaan syndrome patients with severe lymphatic disease, conditionsModule conditions: Lymphatic System Disorders Congenital, conditions: Lymphatic Diseases, conditions: Noonan Syndrome, conditions: Lymphatic Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Dynamic contrast-enhanced lymphangiography, outcomesModule primaryOutcomes measure: Central lymphatic system anatomy and flow descriptive parameters., primaryOutcomes measure: Diameter Thoracic duct, primaryOutcomes measure: Lymph flow velocity, otherOutcomes measure: Demographics age, otherOutcomes measure: Demographics gender, otherOutcomes measure: Demographics, otherOutcomes measure: Demographics weight, otherOutcomes measure: Demographics clinical history, otherOutcomes measure: Demographics genetic background, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Radboudumc, status: RECRUITING, city: Nijmegen, state: Gelderland, zip: 6500 HB, country: Netherlands, contacts name: Lotte ER Kleimeier, Msc, role: CONTACT, phone: 024036106873, email: lotte.kleimeier@radboudumc.nl, geoPoint lat: 51.8425, lon: 5.85278, hasResults: False
protocolSection identificationModule nctId: NCT06267794, orgStudyIdInfo id: ODISEA Study, briefTitle: Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis., acronym: ODISEA, statusModule overallStatus: COMPLETED, startDateStruct date: 2015-06-26, primaryCompletionDateStruct date: 2021-12-30, completionDateStruct date: 2023-03-24, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Jorge L Poo, class: OTHER, descriptionModule briefSummary: This will be a multicenter, double-blind clinical trial to evaluate the safety and efficacy of two doses of prolonged release pirfenidone, compared against placebo plus conventional therapy in patients with compensated liver cirrhosis. The study will be conducted in compliance with International Standard good clinical practices (GCPs) and the Declaration of Helsinki. The protocol is approved by a local Institutional Review Board and registered in clinical trials.gov., conditionsModule conditions: Liver Fibrosis, conditions: Cirrhosis, Liver, conditions: Chronic Liver Disease, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Double blind, placebo-controlled multicenter study, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: Placebo will be identical to medication.Methods to assign treatment:Before assigning numbers to subjects, the researcher must confirm that the inclusion criteria have been met, that none of the exclusion criteria apply, that written and signed informed consent has been obtained, that the evaluations of the scrutiny (of admission) and that the required laboratory results are available and meet the admission criteria. To do this, the centers will be assisted with a check list format that contains all the selection criteria.The person responsible for the medication at the research site will contact the Randomization center, where the treatment will be assigned to the patient., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 180, type: ACTUAL, armsInterventionsModule interventions name: Pirfenidone 1200 mg, interventions name: Pirfenidone 1800 mg, interventions name: Placebo, outcomesModule primaryOutcomes measure: Change in liver fibrosis, primaryOutcomes measure: Clinical side effects, secondaryOutcomes measure: Improvement in Child Pugh score, secondaryOutcomes measure: Improvement in MELD score, secondaryOutcomes measure: Improvement in bilirrubin and albumin, secondaryOutcomes measure: Improvement in prothrombin time, secondaryOutcomes measure: Improvement in liver enzymes, secondaryOutcomes measure: Improvement in EuroQol Visual analog scales, secondaryOutcomes measure: Improvement in EuroQol five dimensions Scale, secondaryOutcomes measure: Improvement in modified fatigue impact scale (MFIS), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False